Journal of International Psychiatry

[Abstract] Objective: to analyze the effect of atorvastatin calcium combined with a new type of etovastatin on patients with coronary heart disease (CHD) and the effect on depression and anxiety score. Methods: 36 CHD patients who received treatment from January 2020 to January 2020 and treated with atorvastatin calcium were treated as control group. 36 CHD patients who received treatment at the same time and were treated with new type of Yifu maibub were treated as observation group. The blood lipid related indexes, serum inflammatory factors, depression anxiety score, adverse reactions rate and clinical effect were analyzed. Results: (1) there was no significant difference in the blood lipid related indexes, serum inflammatory factors and depression anxiety scores before treatment (P > 0.05); The blood lipid related indexes, serum inflammatory factors and depression anxiety scores in the observation group were better than those in the control group after 1 month treatment, P < 0.05（ 2) There was no significant difference between the observation group and the control group (8.33%) during the treatment period (P > 0.05), and the adverse reactions were mild, which did not affect the treatment process（ 3) After one month, 2 cases in the observation group were invalid (5.56%), 9 cases in the control group were invalid (25.00%), P < 0.05. Conclusion: the treatment of atorvastatin calcium + new type of yifold maibub in CHD patients has less adverse reactions, and can enhance the curative effect, improve the inflammatory response and blood lipid index, reduce the scores of depression and anxiety, which is worth popularizing.

Keywords: atorvastatin calcium; New type of etomectin; Coronary heart disease; Depression score; Anxiety score